Its a great moment for big food, big ag, and industry to do a self reflection and analysis of, how did we arrive here? How did we arrive to a world where the folks that picked the produce out of the field dont have access and or make enough to buy the very produce that theyre picking? Rolando Perez, graduate student and volunteer at Xinampa
Biotechnology is on the precipice of changing our world forever. Using solutions always there in biology and optimizing them with technology, biotech promises to solve global issues such as carbon emissions, plastic and chemical pollution, and, of course, feeding a booming population. But to really solve the issue of food, the industry needs to revolutionize more than just biology or technology. It needs to revolutionize the way it engages local cultures and economies. It will not be an easy task, a straightforward task, or a quick task. But it can be done and the people of the world depend on it being done right.
Climate change and population growth have led to predictions that the global population will reach nearly 10 billion people by 2050. Current food production processes cant keep pace with that growth. Fearing an existential crisis, several companies have adopted a tag line that goes something like this: we will feed the world through innovative biotechnologies that are more sustainable and make healthy food more accessible. And theyve got the sustainability beat down: from leveraging microbes to feed plants and reduce toxic nitrogen run-off to improved aquaculture techniques to genetic engineering foods to be more nutritious, the possibilities for producing ever more nutritious food while using less of the Earths precious resources are boundless and already in motion.
But what, exactly, does it mean for food to be accessible in todays world?
Food desert a term used to describe areas with limited access to affordable and nutritious food is the label by which weve come to describe food accessibility today. But the term is a bit of a misnomer, says Garrett Broad, author of More Than Just Food.
It suggests theres nothing there and if food deserts are the problem, the solution sounds pretty simple: just bring [stuff] to the desert.
But is there really nothing there? According to a recent New York Times exposition on the obesity epidemic in Brazil (and in big industrys role in that), there are now more obese people in the world than underweight people. Its as if the pendulum has swung the other direction where hunger was once a very real problem as a result of access to food, period, now obesity, diabetes, and heart disease prevail as a result of access to high calorie, nutrient-poor foods. This has created a new type of malnutrition, write Andrew Jacobs and Matt Richtel, one in which a growing number of people are both overweight and undernourished.
So, continues Broad, the problem isnt food deserts [per se], the problem is really a legacy and generational disinvestment in and direct discrimination in not just food but in a variety of other arenas. [This] calls for a broader set of solutions.
Said another way, the issue of food accessibility is multi-faceted and therefore cannot be solved solely through biotechnology we must come to terms with that fact at the get go. That isnt to say biotechnology cant make the food production system as a whole better. With advances in gene editing and other technologies, we can use technology to improve the nutritional profile of food (tackling malnutrition), to enable seasonable crops to be available all year round (increasing accessibility in one sense), to remove undesired characteristics such as cherry pits (increasing accessibility in another sense), and to make food more resistant to drought, one of the biggest factors influencing a significant proportion of the world populations access to food. But none of this matters if we keep operating under our current system, which, according to Broad, bottom-lines on profit margins, not on feeding people healthily and sustainably.
The biotechnological revolution can give the food industry and low-income disadvantaged communities a chance to hit the reset button to learn from the current state of affairs and prevent the inevitable shortfall of the big promises being made by biotechnology today if we dont change the societal, political, and economic backbone of the way food is made and distributed. And according to Ana Ibarra and Rolando Perez, volunteers at Salinas Valley-based Xinampa (a bio-hub aiming to support equitable economic development, workforce development, small business incubation, and scientific literacy and education), such sea change will come from getting people from all walks of life to sit down together and talk.
From left: Steven Rhyans, Anna Ibarra-Castro, Leo Tejeda, Omar Perez, Matias Kaplan, Rolando Perez. Photo credit: Steven Rhyans
Many of the communities most affected by food inequality are disadvantaged, underrepresented cultural and ethic groups, such as the Hispanic/Latinx and indigenous populations served by Xinampa. Salinas, California, where Xinampa is based, is over 75% Hispanic or Latinx and it is this population that is the life blood of one of the richest agricultural areas in the world. Xinampa is especially passionate about teaching young people high school and college students how they can use biotechnology in their future careers and to bolster their local communities. Ibarra says that young people will be critical for speeding up the development of technologies, a crucial goal given the issues we have at a global scale to sustain human life in light of climate change, decreasing arable land. The younger generations have the ability and talent to carry this forward, she says, and I believe its crucial to start engagement at a young age.
But, Perez is careful to point out, it isnt just about reaching the young.
The work here is intergenerational, and thats really important. There has to be engagement across the whole intergenerational spectrum the bio belt could be about finding opportunities for retirees to do things in the community plant gardens that produce nutritious produce for the community, for example. The next generation is like the seventh generation. You can say seven generations in the future, seven generations in the past, or you can strategically place yourself in the middle of those seven generations; something I learned from a close friend and that has helped me understand my role as a community member and citizen of our planet.
Emphasizing culture and recognizing that the community as a whole, and in particular indigenous communities, has deep-seeded, critical knowledge about agriculture is a core value of Xinampa. Instead of feeding people the all-too-often heard script of you guys just dont know anything, youre eating unhealthy, and were here to change you, they recognize and encourage the generations of knowledge and cultural richness that will be critical for effectively governing and incorporating biotechnology into our future food systems.
What the most successful groups that work around food at the grassroots level do is they push past those scripts, and they open up some storytelling about peoples cultural histories through food, says Broad, and that allows folks to claim knowledge about food and cooking and agriculture, which makes them much more likely to have ownership in this whole conversation.
And the whole conversation must also engage policy makers, those involved in the public health care system, industry leaders essentially anyone that could be affected by biotechnology.
One of the solutions that we could employ to address these inequities is to look to the expertise of individuals in public health, policy, social welfare, or other disciplines that are exposed to issues through a different lens and can provide a different point of view, says Ibarra, adding that its important to foster interdisciplinary conversation early on. We dont want to miss something. We dont want to invest in a solution that may not be the most effective simply because you forgot to include someone in the conversation. Early engagement is how these nutritious and novel foods will be cultivated from the ground up for the benefit of everyone in society.
One of the reasons early involvement in conversation will enable effective distribution of food to everyone is rooted in money. According to Broad, one of the biggest reasons why mistrust in GMOs and how GMO foods could solve some big problems isnt because companies havent been transparent. Its because people look at the big players, the companies in charge, and see companies that havent made their lives substantively better. People recognize that priorities within the biotech industry have not necessarily always been first and foremost about feeding the world equitably and sustainably but instead about who profits from certain biotechnological developments, says Broad. This erodes trust rather than building it.
A great way to build long standing trust is to have equitable distribution of the material wealth that gets created from these innovations. Essentially, how do we think about the development of these tools in an equitable and inclusive way in terms of economic development and economic opportunity? The best way to do this is to get people involved from early on and give them an economic stake so you develop companies that people are engaged in and involved in. That would be something for entrepreneurs and communities like [SynBioBeta] to be thinking about from an early stage, as opposed to thinking about it as kind of a PR approach that comes at the very end.
Its the economy stupid, he continues. Its that classic line if people can see that their economic and social life is going to benefit from these new innovations, then theyre much more likely to be interested in supporting them and have less fear, he says.
Ibarra agrees.
There is a lot of fear around automation and AI, including in communities like ours where the fear is robots are going to come in and pick produce and there will be less jobs for our laborers, she says. But I think the opportunities deriving from biotechnology have an even greater potential. In Monterey County we have a very robust economy resulting from direct and indirect agricultural jobs, but also a significant multiplier effect. If we couple new agricultural technologies, such as automation and AI, with biotechnology in parallel, you can see this allowing communities especially rural ones to be more resilient. Its a real opportunity.
This is critical for communities like Salinas Valley, where homelessness rates in elementary schools can be as high as 50 percent. According to Ibarra, agricultural communities like Salinas are the perfect place to cultivate regenerative biotechnologies that enrich our food systems and advance public health. She and Perez imagine a future for Salinas Valley completely transformed by biotechnology rooted in racial and class equity and justice. For example, Central Coast residents could create public interest biotechnologies that emphasize community control and governance, with investment in people, infrastructure, automation, and supply-chains that extend into the community and that connect to the Valleys world-class global supply-chains. Biotechnology can also be leveraged to produce nutritious crop varieties that adapt plant morphology to make harvesting by hand easier or gene drives to combat invasive pests such as the Asian Citrus Psyllid. Animal agriculture could benefit as well, with new veterinary biotechnological tools to better care for livestock and protect them from disease. Water systems could benefit as well, from cleaning the Salinas River through mycoremediation to employing biosensors to monitor city water for pollution, pesticides, and other chemicals.
In December 2019, Golden Rice was approved for direct use in the Philippines the first Asian country to grant the controversial food approval. Some expect that the added Vitamin A present in the rice will reduce by up to 50% vitamin A deficiency, the leading cause of child mortality in the country. But, others are skeptical that the rice will be the simple solution Filipinos have been waiting for, pointing out that vitamin A deficiency is a complex problem partially rooted in culture, political economics, education, and access. In essence, Golden Rice is the perfect example of both the promise of biotechnology in agriculture and its shortcomings if we dont think critically about all sides of the issue. With up and coming companies like Pairwise Plants and others using biotechnology to produce food that is more nutritious and can be available year-round, it is critical that we heed voices like Broad, Ibarra, and Perez so that technologies that can really make a difference in how we feed the world dont meet the same fate as Golden Rice.
It is possible to feed the world with biotechnology. But its only possible if our goal isnt to feed the world, but to engage local communities, support early, equitable, and inclusive communication, and to ensure that food equity doesnt just mean that everyone can afford to buy healthy food, but that the communities producing that food have equitable economic stake. Move over, big ag its time to take biotechnology from farm to table.
Read the original post:
Why biotech's goal should not be to feed the world - SynBioBeta
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022